InflaRx N.V.(IFRX) - 2023 Q1 - Quarterly Report

Exhibit 99.1 InflaRx Reports Full Year 2022 Financial and Operating Results ● Major progress in development of vilobelimab Jena, Germany, March 22, 2023 – InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti- inflammatory therapeutics by targeting the complement system, today announced financial and operating results for the year ended December 31, 2022. Prof. Niels C. Riedemann, CEO and Founder of InflaRx, commented: "We are very pleased with the exceptional progress we h ...